Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy.

IF 2.6 3区医学 Q1 OTORHINOLARYNGOLOGY

Otolaryngology- Head and Neck Surgery Pub Date : 2025-06-01 Epub Date: 2025-03-07 DOI:10.1002/ohn.1205

Abdurrahman Al-Awady, Vivek Annadata, Ryan Sicard, Avanish Yendluri, Joshua Rosenberg, Mingyang Gray

{"title":"Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy.","authors":"Abdurrahman Al-Awady, Vivek Annadata, Ryan Sicard, Avanish Yendluri, Joshua Rosenberg, Mingyang Gray","doi":"10.1002/ohn.1205","DOIUrl":null,"url":null,"abstract":"Objective: This study examines whether the timing of botulinum toxin type A (BoNTA) treatments affects outcomes in patients with synkinesis, a sequela of Bell's Palsy characterized by disconjugate facial muscle movement.Study design: A retrospective chart review.Setting: An urban academic medical center.Methods: We reviewed the charts of synkinesis patients treated from 2016 to 2022. Data included procedural notes, intervention dates, and scores from the House-Brackmann (HB), Facial Clinimetric Evaluation (FaCE), Synkinesis Assessment Questionnaire (SAQ), and Facial Grading System (FGS).Results: Sixty-seven patients (median age 54 years, average palsy duration 5.7 years) received BoNTA. Patients treated within 12 months (n = 28), 13 to 24 months (n = 12), and after 24 months (n = 23) showed no significant differences in changes to HB, FaCE, or SAQ scores. However, patients treated within 1 year had significantly higher FGS improvement (36.3) than the other groups (P = .03).Conclusion: While FaCE, HB, and SAQ scores showed no significant differences, early BoNTA treatment within 1 year significantly improved FGS scores, indicating better outcomes. Therefore, early treatment is ideal for optimal response.","PeriodicalId":19707,"journal":{"name":"Otolaryngology- Head and Neck Surgery","volume":" ","pages":"1897-1903"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otolaryngology- Head and Neck Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ohn.1205","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study examines whether the timing of botulinum toxin type A (BoNTA) treatments affects outcomes in patients with synkinesis, a sequela of Bell's Palsy characterized by disconjugate facial muscle movement.

Study design: A retrospective chart review.

Setting: An urban academic medical center.

Methods: We reviewed the charts of synkinesis patients treated from 2016 to 2022. Data included procedural notes, intervention dates, and scores from the House-Brackmann (HB), Facial Clinimetric Evaluation (FaCE), Synkinesis Assessment Questionnaire (SAQ), and Facial Grading System (FGS).

Results: Sixty-seven patients (median age 54 years, average palsy duration 5.7 years) received BoNTA. Patients treated within 12 months (n = 28), 13 to 24 months (n = 12), and after 24 months (n = 23) showed no significant differences in changes to HB, FaCE, or SAQ scores. However, patients treated within 1 year had significantly higher FGS improvement (36.3) than the other groups (P = .03).

Conclusion: While FaCE, HB, and SAQ scores showed no significant differences, early BoNTA treatment within 1 year significantly improved FGS scores, indicating better outcomes. Therefore, early treatment is ideal for optimal response.

查看原文本刊更多论文

A型肉毒毒素对贝尔氏麻痹后联动性患者的定时疗效。

目的：本研究探讨A型肉毒杆菌毒素（BoNTA）治疗的时机是否会影响以面部肌肉运动分离为特征的贝尔麻痹后遗症-联动症患者的预后。研究设计：回顾性图表回顾。环境：城市学术医疗中心。方法：回顾2016 - 2022年共动症患者病历。数据包括手术记录、干预日期、House-Brackmann （HB）评分、面部临床评价（FaCE）、综合评价问卷（SAQ）和面部评分系统（FGS）。结果：67例患者（中位年龄54岁，平均瘫痪时间5.7年）接受BoNTA治疗。在12个月内（n = 28）、13至24个月（n = 12）和24个月后（n = 23）接受治疗的患者HB、FaCE或SAQ评分的变化无显著差异。然而，1年内治疗的患者FGS改善（36.3）明显高于其他组（P = .03）。结论：虽然FaCE、HB和SAQ评分无显著差异，但早期BoNTA治疗1年内可显著提高FGS评分，表明预后较好。因此，早期治疗是获得最佳疗效的理想选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Otolaryngology- Head and Neck Surgery 医学-耳鼻喉科学

CiteScore

6.70

自引率

2.90%

发文量

250

审稿时长

2-4 weeks

期刊介绍： Otolaryngology–Head and Neck Surgery (OTO-HNS) is the official peer-reviewed publication of the American Academy of Otolaryngology–Head and Neck Surgery Foundation. The mission of Otolaryngology–Head and Neck Surgery is to publish contemporary, ethical, clinically relevant information in otolaryngology, head and neck surgery (ear, nose, throat, head, and neck disorders) that can be used by otolaryngologists, clinicians, scientists, and specialists to improve patient care and public health.